Reported 1 day ago
Eli Lilly is preparing for the launch of its experimental oral weight-loss drug orforglipron by building a pre-launch inventory worth nearly $550 million, as reported in its financial statements. This strategy is atypical for such a long lead time before launch, anticipated in 2026, and reflects Lilly's proactive approach to secure a competitive edge in the market against rival companies like Novo Nordisk and AstraZeneca. Analysts suggest that this inventory indicates significant sales potential, possibly reaching $10 billion by 2024.
Source: YAHOO